Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Ovarian Neoplasms 17Fallopian Tube Neoplasms 17Carcinoma, Non-Small-Cell Lung 8Glioblastoma 7Carcinoma, Renal Cell 7Lung Neoplasms 6Colorectal Neoplasms 6Brenner Tumor 6Squamous Cell Carcinoma of Head and Neck 5Melanoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Gliosarcoma 4Breast Neoplasms 4Brain Neoplasms 4Recurrent Squamous Cell Lung Carcinoma 3Oligodendroglioma 3Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Uveal Melanoma 2Urinary Bladder Neoplasms 2Spinal Cord Neoplasms 2Medulloblastoma 2Glioma 2Endometrial Adenocarcinoma 2Colonic Neoplasms 2Carcinoma 2Astrocytoma 2Adenocarcinoma of Lung 2

Interventions

Rituximab 134Cyclophosphamide 100Vincristine 53fludarabine phosphate 50Prednisone 50Doxorubicin 49Etoposide 47Peripheral Blood Stem Cell Transplantation 38Mycophenolic Acid 37Whole-Body Irradiation 35Tacrolimus 29Busulfan 27Lenalidomide 26Filgrastim 26Cyclosporine 26Melphalan 24Methotrexate 21Antilymphocyte Serum 21Gemcitabine 18ibritumomab tiuxetan 17Granulocyte Colony-Stimulating Factor 17Cytarabine 17Carmustine 16Radiotherapy 15fludarabine 14Carboplatin 14Bendamustine Hydrochloride 14pembrolizumab 13ibrutinib 12Sirolimus 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Lymphoma, Large B-Cell, Diffuse × Immunoglobulin G × Clear all
NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT03309878 2023-09-21

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
8 enrolled 10 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02706405 2022-08-24

JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Terminated
30 enrolled 29 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡